For how we live.
In a 180-infant phase 1/2 trial, a live-attenuated intranasal RSV vaccine raised neutralising antibodies in two-thirds or more of RSV-naive babies but barely budged those already exposed. Sanofi funded the study.
A phase 2b trial in 4936 Gambian children missed its primary endpoint, but ETVAX cut moderate-to-severe ETEC diarrhoea by 80.6% once parasite co-infections were excluded.
Every vaccine does the same job — teach the immune system to recognise a pathogen before it arrives. What differs is how they show it the target: live, inactivated, protein, viral vector, or mRNA.
In a 20,000-child trial across eight endemic countries, TAK-003 was 61.2% effective against symptomatic dengue and 84.1% against hospitalisation — but protection was narrower in children never previously infected.
An 18,476-person phase 3 trial and a small human challenge study landed the same day. Both favour the mRNA vaccine against influenza A; neither settles what it does against influenza B.